撤稿:微钙化相关乳腺癌中HER2富集分子亚型与乳腺X线摄影特征相关
研究纳入283例微钙化相关乳腺癌(HER2富集型57例,非HER2富集型226例),分析乳腺X线摄影的肿块与钙化特征与HER2分子亚型的关系。单因素分析显示HER2富集型在肿瘤≤2 cm、非毛刺状肿块、钙化范围>2 cm及钙化密度>20 cm⁻²时比例更高;多因素分析中肿瘤大小、毛刺状肿块和钙化范围是独立预测因子,模型AUC为0.751。
要点
- 微钙化相关乳腺癌中,小肿瘤(≤2 cm)更常见于HER2富集型(57.9% vs 9.7%,p=0.007)。
- 非毛刺状肿块更常见于HER2富集型(68.4% vs 7.9%,p=0.034)。
- 钙化范围>2 cm更常见于HER2富集型(71.9% vs 7.1%,p<0.001)。
核心结论
- 结合肿瘤大小、非毛刺状肿块和钙化范围的乳腺X线摄影特征预测模型可能用于术前预测乳腺癌HER2富集亚型,模型AUC为0.751(95%CI 0.701–0.854)。
研究设计与样本
- 研究纳入283例微钙化相关乳腺癌(HER2富集型57例,非HER2富集型226例),分析乳腺X线摄影的肿瘤肿块和钙化特征与HER2分子亚型的关系。
关键影像表现/征象
- 肿瘤大小≤2 cm的病灶中HER2富集型率为57.9%(33/57),肿瘤大小>2 cm的病灶中为9.7%(22/226),p=0.007。
- 非毛刺状肿块的病灶中HER2富集型率为68.4%(39/57),毛刺状肿块的病灶中为7.9%(18/226),p=0.034。
- 钙化范围>2 cm的病灶中HER2富集型率为71.9%(41/57),钙化范围≤2 cm的病灶中为7.1%(16/226),p<0.001。
- 钙化密度>20 cm⁻²的病灶中HER2富集型率为71.2%(44/57),钙化密度≤20 cm⁻²的病灶中为5.8%(13/226),p=0.034。
诊断标准与关键数值
- 多因素分析中,肿瘤大小>2 cm vs ≤2 cm的OR为0.415(95%CI 0.215–0.802),p=0.009。
- 多因素分析中,毛刺状肿块 vs 非毛刺状肿块的OR为0.226(95%CI 0.114–0.446),p<0.001。
- 多因素分析中,钙化范围>2 cm vs ≤2 cm的OR为7.754(95%CI 3.100–19.339),p<0.001。
- 预测模型的AUC为0.751(95%CI 0.701–0.854)。
临床应用与阅片要点
- 作者认为,小肿瘤、非毛刺状肿块和钙化范围>2 cm更可能为HER2分子亚型。
- 作者指出,该预测模型可能用于术前预测乳腺癌HER2富集亚型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate whether the mammographic features were different between breast cancer HER2-enriched molecular subtype and non-HER2-enriched molecular subtype.
METHODS: 283 microcalcification-associated breast cancers were identified (HER2-enriched: n = 57; non-HER2-enriched: n = 226). Mammographic tumor mass and calcification features in relation to HER2 molecular subtype were analyzed.
RESULTS: On univariate analysis, HER2-enriched molecular subtype rates were significantly higher (a) in tumor size ≤2 cm [33 of 57 (57.9%)] than in tumor size >2 cm lesions [22 of 226 (9.7%)] (p = 0.007), (b) in non-spiculated mass [39 of 57 (68.4%)] than in spiculated mass lesions [18 of 226 (7.9%)] (p = 0.034),(c) in calcifications extent >2 cm [41 of 57 (71.9%)] lesions than in calcifications extent ≤2 cm lesions [16 of 226 (7.1%)] (p < 0.001) and (d) in calcification density >20 cm-2 [44 of 57 (71.2%)] lesions than in calcification density ≤20 cm-2 lesions [13 of 226 (5.8%)] (p = 0.034).On multivariate analysis, three mammographic features [tumor size >2 cm vs size ≤2 cm odds ratio (OR): 0.415 95% confidence interval (CI) (0.215 to 0.802), p = 0.009, spiculated mass vs non-spiculated mass OR: 0.226 95% CI (0.114 to 0.446), p < 0.001 and calcifications extent >2 cm vs calcifications extent ≤2 cm OR: 7.754, 95% CI (3.100 to 19.339) p< 0.001] were independent predictors. Our results indicated that small tumor size, non-spiculated mass and calcification extent >2 cm are more likely to be HER2 molecular subtype. The discrimination of this model, as quantified by the area under the curve, was 0.751 [95% CI (0.701 to 0.854)].
CONCLUSION: Our study presents a prediction model that incorporates the mammographic features of tumor size, non-spiculated mass and calcification extent, which can potentially be used to preoperative predict breast cancer HER2-enriched subtype.
ADVANCES IN KNOWLEDGE: Mammographic features can noninvasively visualize breast tumor phenotype characteristics.
引用
- Nie Z, Wang J, Ji XC, et al. Retracted: Microcalcification-associated breast cancer: HER2-enriched molecular subtype is associated with mammographic features. Br J Radiol. 2021. PMID: 29927639. doi:10.1259/bjr.20170942
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。